Hegln Pharmaceutical Co. Ltd., Urodynamix deal

Urodynamix plans to sell the majority of its assets to Hegln for C$2.1 million ($2 million). The deal includes Urodynamix's near-infrared spectroscopy (NIRS) business and its uroNIRS 2000. The test us...